1. Home
  2. BNR vs OABI Comparison

BNR vs OABI Comparison

Compare BNR & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$16.86

Market Cap

252.7M

Sector

Health Care

ML Signal

HOLD

Logo OmniAb Inc.

OABI

OmniAb Inc.

HOLD

Current Price

$1.41

Market Cap

237.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNR
OABI
Founded
2014
2012
Country
China
United States
Employees
N/A
89
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
252.7M
237.4M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
BNR
OABI
Price
$16.86
$1.41
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.50
AVG Volume (30 Days)
23.7K
547.8K
Earning Date
06-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$111.65
$52.42
Revenue Next Year
N/A
$64.69
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.18
$1.22
52 Week High
$41.72
$2.22

Technical Indicators

Market Signals
Indicator
BNR
OABI
Relative Strength Index (RSI) 39.04 36.71
Support Level $15.61 $1.32
Resistance Level $23.19 $1.70
Average True Range (ATR) 1.60 0.09
MACD 0.09 -0.00
Stochastic Oscillator 14.93 3.92

Price Performance

Historical Comparison
BNR
OABI

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

About OABI OmniAb Inc.

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

Share on Social Networks: